Modus Therapeutics appoints new VP of Development
Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, announces the appointment of Lena Jendeberg as its new Vice President of Development.
Lena Jendeberg joins Modus Therapeutics from Swedish Orphan Biovitrum AB (Sobi), where she was Global Program Director, Project & Portfolio Management and Strategic Operations from 2010. In this role she was primarily responsible for Life Cycle Management of one of Sobi’s key products Kineret (anakinra) – a drug used for home treatment by patients suffering from RA or Neonatal Onset Multisystem Inflammatory Disease. Prior to this she was Program Director of Hemophilia at Biovitrum.
Lena holds an MSc in Chemical Engineering and PhD in Biochemistry/Biotechnology from the Royal Institute of Technology, KTH, Stockholm.
Lena said: “I am excited to join the Modus Therapeutics team, and look forward to contributing to the company’s continued success as we proceed with the clinical development of our lead candidate sevuparin, which we believe can become an important treatment for the vaso-occlusive crises experienced by Sickle Cell Disease patients.”
Christina Herder, CEO of Modus Therapeutics said: “We are pleased to welcome Lena to the company at this exciting time. Lena brings to Modus Therapeutics strong cross functional leadership from research to commercialization, based on her extensive knowledge of drug development gained from more than 15 years of experience.”
Modus Therapeutics is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East. Results from this Phase II trial with sevuparin are expected in the second half of 2016.